NGEN
NervGen Pharma Corp.
1.90$
-3.1%
vs. previous close
Closing price · As of: Sep 28, 2026
Statements
Cash Flow
NervGen Pharma Corp. (NGEN) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -19 million CAD. Tick rows to compare them in a chart.
All figures in millions of CAD.
Tick rows to compare them in a chart (up to 4)
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| -1.0 | -8.3 | -6.3 | -8.3 | -18 | -11 | -17 | -19 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | |
| – | – | – | – | 2.8 | 6.0 | 6.0 | 5.4 | |
| 0.3 | 0.2 | 1.4 | 0.4 | 2.1 | -0.2 | 0.8 | 0.7 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| -0.1 | – | 0.0 | 0.0 | 0.0 | -0.1 | 0.1 | 0.1 | |
| – | – | – | – | -0.1 | -0.1 | -0.1 | -0.1 | |
| 3.6 | 10 | 7.9 | 20 | 22 | 0.8 | 23 | 24 | |
| 2.5 | 1.8 | 1.6 | 11 | 4.3 | -10 | 4.6 | 4.8 | |
| -1.0 | -8.3 | -6.3 | -8.3 | -18 | -11 | -17 | -19 |
Data as of: September 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.